In brief
- A panel of 32 experts from eight countries in the South Asian Association for Regional Cooperation (SAARC) region has published region-specific consensus recommendations for the diagnosis and treatment of non-small cell lung cancer (NSCLC).
- The panel voted on 174 statements through a Delphi process of three rounds of online meetings and three rounds of voting.
- A statement was accepted when more than 75% of the experts voted to accept it completely or with reservation.
- Because of affordability problems in the region, the recommendations include evidence-based low-cost and low-dose options.
- The abstract does not list the individual recommendations or report how many statements reached consensus.
A region with no lung cancer guidelines of its own
The authors describe the SAARC countries as carrying a high cancer burden alongside inadequate infrastructure, a shortage of skilled healthcare professionals, poor access to diagnostics and the latest treatments, and limited affordability. NSCLC is among the leading cancers in the region, yet no region-specific guidelines were available.
The panel’s starting point was an exchange of information on the facilities available in each member country and the problems clinicians there face in treating NSCLC.
174 statements put to three rounds of Delphi voting
The 32 panel members voted on 174 statements drawn from international and regional evidence. Over three rounds of online meetings and three rounds of voting, statements were modified where necessary. A recommendation was kept when more than 75% of the experts accepted it, either completely or with reservation.
The acceptance rule counts a vote of acceptance with reservation the same as full acceptance, so a statement can pass even when many of those voting for it hold reservations. The abstract does not report how often that happened.
Low-cost and low-dose options written into the statements
The statements cover diagnosis, staging and risk assessment; early-stage disease; resectable and unresectable locally advanced disease; and metastatic disease with and without molecular drivers. Separate statements address older patients, bone and brain metastases, oligometastatic and oligorecurrent disease, and follow-up.
Alongside these, the panel included statements proposing evidence-based low-cost or low-dose options, in response to the affordability problems it had described.
“These consensus recommendations will help oncologists in SAARC countries to make treatment decisions across the spectrum of NSCLC.”Prabhash et al., Clinical Lung Cancer (2026)
The abstract gives no breakdown of the panel by country or specialty, and it does not identify which treatments the low-cost and low-dose statements concern. Readers will need the full paper for the recommendations themselves.
Sources
- Clinical Lung Cancer. SAARC Consensus Recommendations for the diagnosis and treatment of non-small-cell lung cancer (NSCLC) (2026-11-01). doi.org
Featuring Lung Summit faculty
This study was co-authored by Lung Summit faculty Vanita Noronha.
This article was produced independently by the Lung Summit editorial team, without industry funding or input.